Clinical Trial Update: Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment [Phase 2, Phase 3]

View source ↗

Summary

A trial update on acalabrutinib and venetoclax for newly diagnosed CLL patients at high infection risk or early treatment phase (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: CLL | Phase 2, Phase 3 | Status: RECRUITING